IL-28B polymorphisms and treatment response in hepatitis c virus patients with persistently normal alanine aminotransferase

World Journal of Hepatology

Volumn 5, Issue 11, 2013, Pages 635-641

  Miyamura, Tatsuo ^a   Kanda, Tatsuo ^a   Nakamura, Masato ^a   Jiang, Xia ^a   Wu, Shuang ^a   Nakamoto, Shingo ^a   Mikami, Shigeru ^b   Takada, Nobuo ^c   Imazeki, Fumio ^a   Yokosuka, Osamu ^a  

^a CHIBA UNIVERSITY   (Japan)

^b Kikkoman General Hospital   (Japan)

^c TOHO UNIVERSITY   (Japan)

Author keywords

Hepatitis C virus; Interleukin 28B; Persistent normal alanine aminotransferase levels; Standard of care; Treatment response

Indexed keywords

EID: 84890586317     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v5.i11.635     Document Type: Article

References (35)

1. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Semin Liver Dis 1995; 15: 64-69 [PMID: 7597445 DOI: 10.1055/ s-2007-1007263]
2. Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuchi S, Watanabe Y, Koi S, Onji M, Ohta Y. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 1990; 87: 6547-6549 [PMID: 2168552]
3. Tan A, Yeh SH, Liu CJ, Cheung C, Chen PJ. Viral hepatocarcinogenesis: from infection to cancer. Liver Int 2008; 28: 175-188 [PMID: 18251977 DOI: 10.1111/j.1478-3231.2007.01652.x]
4. Kanda T, Imazeki F, Yokosuka O. New antiviral therapies for chronic hepatitis C. Hepatol Int 2010; 4: 548-561 [PMID: 21063477 DOI: 10.1007/s12072-010-9193-3]
5. Lagging M, Rembeck K, Rauning Buhl M, Christensen P, Dalgard O, Färkkilä M, Hellstrand K, Langeland N, Lindh M, Westin J, Norkrans G. Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse. Scand J Gastroenterol 2013; 48: 839-847 [PMID: 23795661 DOI: 10.3109/00365521.2013.793389]
6. Yu ML, Huang CF, Huang JF, Chang NC, Yang JF, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Li YN, Wu MS, Dai CY, Juo SH, Chuang WL. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 2011; 53: 7-13 [PMID: 21254157 DOI: 10.1002/hep.23976]
7. Nunnari G, Pinzone MR, Cacopardo B. Lack of clinical and histological progression of chronic hepatitis C in individuals with true persistently normal ALT: the result of a 17-year follow-up. J Viral Hepat 2013; 20: e131-e137 [PMID: 23490382 DOI: 10.1111/jvh.12029]
8. Omata M, Kanda T, Yu ML, Yokosuka O, Lim SG, Jafri W, Tateishi R, S. Hamid S, Chuang WL, Chutaputti A, Wei L, Sollano J, Sarin SK, Kao JH, W. McCaughan G. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012; 6: 409-435 [DOI: 10.1007/ s12072-012-9342-y]
9. Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, Shiffman M, Farci P, Gitlin N, O'Brien CB, Lamour F, Lardelli P. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127: 1724-1732 [PMID: 15578510]
10. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374 [PMID: 19330875 DOI: 10.1002/ hep.22759]
11. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264 [PMID: 21371579 DOI: 10.1016/j.jhep.2011.02.023]
12. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401 [PMID: 19684573 DOI: 10.1038/nature08309]
13. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M,Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104 [PMID: 19749758 DOI: 10.1038/ng.447]
14. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109 [PMID: 19749757 DOI: 10.1038/ng.449]
15. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801 [PMID: 19759533 DOI: 10.1038/nature08463]
16. Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, Nischalke HD, Lokhnygina Y, Kullig U, Göbel U, Capka E, Wiegand J, Schiefke I, Güthoff W, Grüngreiff K, König I, Spengler U, McCarthy J, Shianna KV, Goldstein DB, McHutchison JG, Timm J, Nattermann J. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010; 139: 1586-1592, 1592.e1 [PMID: 20637200 DOI: 10.1053/j.gastro.2010.07.005]
17. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shirasaki T, Horimoto K, Tanaka Y, Tokunaga K, Mizokami M, Kaneko S. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139: 499-509 [PMID: 20434452 DOI: 10.1053/j.gastro.2010.04.049]
18. Lagging M, Askarieh G, Negro F, Bibert S, Söderholm J, Westin J, Lindh M, Romero A, Missale G, Ferrari C, Neumann AU, Pawlotsky JM, Haagmans BL, Zeuzem S, Bochud PY, Hellstrand K. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One 2011; 6: e17232 [PMID: 21390311 DOI: 10.1371/journal.pone.0017232]
19. Miyamura T, Kanda T, Nakamoto S, Wu S, Fujiwara K, Imazeki F, Yokosuka O. Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms predict treatment outcomes in hepatitis C virus genotype 1-infected patients. PLoS One 2011; 6: e28617 [PMID: 22174846 DOI: 10.1371/journal. pone.0028617]
20. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, Hergott D, Porter-Gill P, Mumy A, Kohaar I, Chen S, Brand N, Tarway M, Liu L, Sheikh F, Astemborski J, Bonkovsky HL, Edlin BR, Howell CD, Morgan TR, Thomas DL, Rehermann B, Donnelly RP, O'Brien TR. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013; 45: 164-171 [PMID: 23291588 DOI: 10.1038/ng.2521]
21. Bibert S, Roger T, Calandra T, Bochud M, Cerny A, Semmo N, Duong FH, Gerlach T, Malinverni R, Moradpour D, Negro F, Müllhaupt B, Bochud PY. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med 2013; 210: 1109-1116 [PMID: 23712427 DOI: 10.1084/jem.20130012]
22. Sato M, Kato N, Tateishi R, Muroyama R, Kowatari N, LiW, Goto K, Otsuka M, Shiina S, Yoshida H, Omata M, Koike K. IL28B minor allele is associated with a younger age of onset of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. J Gastroenterol 2013 May 22; Epub ahead of print [PMID: 23689989]
23. Hodo Y, Honda M, Tanaka A, Nomura Y, Arai K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Sakai A, Sasaki M, Nakanuma Y, Moriyama M, Kaneko S. Association of interleukin-28B genotype and hepatocellular carcinoma recurrence in patients with chronic hepatitis C. Clin Cancer Res 2013; 19: 1827-1837 [PMID: 23426277 DOI: 10.1158/1078-0432.CCR-12-1641]
24. Agúndez JA, García-Martin E, Maestro ML, Cuenca F, Martínez C, Ortega L, Carballo M, Vidaurreta M, Agreda M, Díaz-Zelaya G, Suárez A, Díaz-Rubio M, Ladero JM. Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease. PLoS One 2012; 7: e37998 [PMID: 22666430 DOI: 10.1371/journal. pone.0037998]
25. Nakamoto S, Kanda T, Imazeki F, Wu S, Arai M, Fujiwara K, Yokosuka O. Simple assay based on restriction fragment length polymorphism associated with IL28B in chronic hepatitis C patients. Scand J Gastroenterol 2011; 46: 955-961 [PMID: 21529139 DOI: 10.3109/00365521.2011.574731]
26. Miyamura T, Kanda T, Nakamoto S, Wu S, Jiang X, Arai M, Fujiwara K, Imazeki F, Yokosuka O. Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin. Viruses 2012; 4: 1264-1278 [PMID: 23012624 DOI: 10.3390/v4081264]
27. Tsukiyama-Kohara K, Yamaguchi K, Maki N, Ohta Y, Miki K, Mizokami M, Ohba K, Tanaka S, Hattori N, Nomoto A. Antigenicities of Group I and II hepatitis C virus polypeptides--molecular basis of diagnosis. Virology 1993; 192: 430-437 [PMID: 7678473]
28. Tanaka T, Tsukiyama-Kohara K, Yamaguchi K, Yagi S, Tanaka S, Hasegawa A, Ohta Y, Hattori N, Kohara M. Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology 1994; 19: 1347-1353 [PMID: 7514558]
29. Puoti C. Hepatitis C virus with normal transaminase levels. Dig Dis 2007; 25: 277-278 [PMID: 17827956]
30. Kobayashi M, Suzuki F, Akuta N, Sezaki H, Suzuki Y, Hosaka T, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Miyakawa Y, Kumada H. Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus. J Gastroenterol 2012; 47: 596-605 [PMID: 22438096 DOI: 10.1007/s00535-012-0531-1]
31. Kanda T, Yokosuka O, Omata M. Treatment of hepatitis C virus infection in the future. Clin Transl Med 2013; 2: 9 [PMID: 23577631 DOI: 10.1186/2001-1326-2-9]
32. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012; 56: 78-84 [PMID: 21827730 DOI: 10.1016/j.jhep.2011.07.016]
33. Hynicka LM, Heil EL. Anemia management in patients with chronic viral hepatitis C. Ann Pharmacother 2013; 47: 228-236 [PMID: 23386076 DOI: 10.1345/aph.1R513]
34. Kanda T, Jiang X, Nakamoto S, Nakamura M, Miyamura T, Wu S, Yokosuka O. Different effects of three interferons L on Toll-like receptor-related gene expression in HepG2 cells. Cytokine 2013; 64: 577-583 [PMID: 24041672 DOI: 10.1016/ j.cyto.2013.08.010]
35. Nakamura M, Kanda T, Miyamura T, Wu S, Nakamoto S, Yokosuka O. Alanine aminotransferase elevation during peginterferon alpha-2a or alpha-2b plus ribavirin treatment. Int J Med Sci 2013; 10: 1015-1021 [PMID: 23801888 DOI: 10.7150/ijms.6402]